Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs

Autor: Hamzah Z. Farooq, David Wyllie, Marieke J. van der Werf, Doris Hillemann, Vladyslav Nikolayevskyy, Csaba Ködmön, Daniela Maria Cirillo
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Microbiology (medical)
Tuberculosis
Epidemiology
030231 tropical medicine
Antitubercular Agents
lcsh:Medicine
Microbial Sensitivity Tests
drugs
drug susceptibility
Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs
lcsh:Infectious and parasitic diseases
Clofazimine
Mycobacterium tuberculosis
respiratory infections
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Antibiotic resistance
Tuberculosis
Multidrug-Resistant
Research Letter
Humans
Medicine
lcsh:RC109-216
030212 general & internal medicine
antimicrobial resistance
Diarylquinolines
bacteria
biology
business.industry
public health
lcsh:R
Drug susceptibility
medicine.disease
biology.organism_classification
Virology
testing
tuberculosis and other mycobacteria
Europe
Infectious Diseases
Pharmaceutical Preparations
chemistry
tuberculosis
Linezolid
Delamanid
Bedaquiline
business
medicine.drug
Zdroj: Emerging Infectious Diseases, Vol 27, Iss 3, Pp-(2021)
Emerging Infectious Diseases
ISSN: 1080-6059
1080-6040
Popis: We surveyed availability of phenotypic drug susceptibility testing for drug-resistant Mycobacterium tuberculosis in Europe. Of 27 laboratories, 17 tested for linezolid, 11 for clofazimine, 9 for bedaquiline, and 6 for delamanid during 2019. Our findings indicate that testing capacity for newer and repurposed tuberculosis drugs exists, but its availability is limited.
Databáze: OpenAIRE
Externí odkaz: